Table 1.
Characteristics of included studies.
| First author | Year | Country | Sample size | Male/female | Mean age (range) | Patients’ primary diseases | ONJ-related drugs | BMAs (molecule type) | Awareness about MRONJ | Source of information |
|---|---|---|---|---|---|---|---|---|---|---|
| Migliorati C.A. | 2010 | USA | 73 | 2/71 | 66 (44–88) | Osteoporosis: 54 (74%); Osteopenia: 16 (22%); Breast cancer: 1 (1%); Unknown: 2 (3%) |
BPs | alendronate: 44 (60%); risedronate: 21 (29%); ibandronate: 7 (10%); zoledronate: 1 (1%) |
13 (18%) | n.d. |
| Bauer J.S. | 2012 | Germany | 55 | 8/47 | 61.9 (45–84) | Osteoporosis: 30 (54.5%); Advanced breast cancer:17 (30.9%); Advanced prostate cancer:8 (14.5%) |
BPs | zoledronate: 20 (36.4%); alendronate: 23 (41.8%); risedronate: 8 (14.5%); ibandronato: 9 (16.4%); pamidronate: 1 (1.8%); Etidronic acid: 2 (3.6%); Diphos®: 1 (1.8%); clodronate: 1 (1.8%) |
15 (27.3%) | Package insert: 34 (62%); Oncologist: 9 (16%); General practitioner: 7 (13%) |
| Al Abdullateef A. | 2020 | Saudi Arabia | 68 | 18/50 | 20–80 | Osteoporosis and cancer patients | BPs, DNB or Aas | n.d. | 23 (33.82%) | Physicians: 17 (70.84%); Nurses 1 (4.17%); Dentists 6 (25%) |
| El-Ma’aita A. | 2020 | Jordan | 110 | 26/84 | 40–78 | Osteoporosis: 87 (79.1%); Osteopenia: 7 (6.4%); Paget disease: 1 (0.9%); Multiple myeloma: 2 (1.8%); Malignancy: 13 (11.8%) |
BPs | n.d. | 15 (12.4%) | Physician: 5 (33%); Dentist: 6 (40%); Self-educated: 1 (6.7%); Other sources: 3 (20%) |
| Hristamyan M. | 2022 | Bulgaria | 112 | 58/54 | 68 (38–85) | Breast cancer: 45 (40.18%); Prostate cancer: 40 (35.71%); Multiple myeloma: 7 (6.25%); Lung cancer: 2 (1.79%); Other: 18 (16.07%) |
BPs | n.d. | 20 (17.86%) | Oncologist: 13 (11.61%); Friend/another patient: 13 (11.61%); Doctor with another specialty:7 (6.25%); Dentist: 3 (2.68%); Internet: 3 (2.68%); Leaflets: 3 (2.68%); General Practitioner: 1 (0.89%) |
| de Lima-Souza R.A. | 2022 | Brazil | 65 | 6/59 | 65.2 (42–82) | Osteoporosis: 59 (90.8%); Breast cancer: 3 (4.6%); Lung cancer: 1 (1.5%); Multiple myeloma 2 (3.1%) |
BPs | alendronate: 57 (87.7%); zoledronate: 10 (15.4%); risedronate: 9 (13.8%); ibandronate 2 (3.1%). |
6 (9.2%) | Dentist: 2 (3.1%); Physicians: 2 (3.1%); Other (television): 2 (3.1%) |